Product category:
Cell/tissue handling and counting
News Release from: Cellomics Europe | Subject: Data Viewer
Edited by the Laboratorytalk Editorial
Team on 05 August 2002
Improved visualisation of cell images
Cellomics Europe has announced the release of a new and enhanced version of its market-leading High Content Screening (HCS) visualisation tool, Cellomics Data Viewer.
Cellomics Europe has announced the release of a new and enhanced version of its market-leading High Content Screening (HCS) visualisation tool, Cellomics Data Viewer Data Viewer provides rich visualisation of cell images and quantitative spatial, temporal, and functional analysis of cells and their constituents
This article was originally published on Laboratorytalk on 11 Oct 2001 at 8.00am (UK)
Related stories
Automation for cell-based drug discovery
The ArrayScan HCS system from Cellomics is a proprietary drug discovery instrument that performs automated measurement and analysis of spatial and temporal events in cells
Hallmark indicators of drug toxicity
The multiparameter Cytotoxicity 1 assay is the latest in Cellomics's series of HitKits, to quantify multiple hallmark indicators of drug toxicity in cells
This comprehensive analysis capability allows the user to visualise multi-feature, cell-based data/images and make comparisons across multiple plates, wells and /or features from any Cellomics HCS Reader.
Some of the key improvements in the new release include full support for all Cellomics HCS Readers and legacy data, faster data load, easier set-up and configuration, an improved graphical user interface and more flexible image and data export functions.
These enhanced capabilities provide the end-user with wider access to HCS data and the ability to rapidly analyse results to make better decisions.
Cellomics is pioneering the field of cellular knowledge extraction.
Its unique technology integrates fluorescent reagents, kits, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetics systems), and information management systems to achieve a flexible, broadly applicable platform for users in the life sciences.
This automated platform, when applied to lead optimisation, predictive toxicology, and new target validation, is proving to reduce the "idea-to-discovery" cycle time in drug discovery, while increasing the probability of the therapeutic success of leads.
• Cellomics Europe: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
